Mar 31, 2025
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Mar 31, 2025
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
Mar 26, 2025
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
Jan 14, 2025
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Nov 13, 2024
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 08, 2024
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Sep 05, 2024
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Aug 19, 2024
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Aug 14, 2024
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 05, 2024
Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
May 14, 2024
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024
Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
Mar 06, 2024
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Mar 01, 2024
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
Feb 26, 2024
Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
Jan 18, 2024
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
Jan 09, 2024
AcelRx Announces Rebranding With Name Change to Talphera, Inc.